Kaftrio

elexacaftor/tezacaftor/ivacaftor, the active ingredient in Kaftrio, is a CFTR modulator presented as a elexacaftor 100 mg / tezacaftor 50 mg / ivacaftor 75 mg oral tablet for oral use. It treats cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation.

GNH USA supplies Kaftrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our global distribution network ensures reliable access to this therapy for eligible patients across Europe, North America, Asia and the Middle East.

Kaftrio is indicated for cystic fibrosis, a genetic disorder affecting the CFTR protein. - Cystic fibrosis (≥12 years, ≥1 F508del mutation): improves lung function and reduces pulmonary exacerbations. - Cystic fibrosis (≥12 years, ≥1 F508del mutation): enhances nutritional status and weight gain. - Cystic fibrosis (≥12 years, ≥1 F508del mutation): decreases sweat chloride concentration reflecting improved CFTR activity.

Kaftrio may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain. - Diarrhea: loose stools. - Nausea: feeling of sickness. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Hepatitis: significant liver inflammation. - Cataracts: clouding of the eye lens. - Severe allergic reaction: including hives, swelling, or anaphylaxis.

When prescribing Kaftrio, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess transaminases before and during therapy. - Ophthalmologic evaluation: perform baseline eye exams and monitor for cataracts. - Drug interaction review: check for concomitant strong CYP3A inducers or inhibitors. - Pregnancy and lactation counseling: discuss unknown safety profile with women of childbearing potential. - Adherence education: emphasize importance of taking tablets with a fatty meal. - Store at ambient temperature: keep tablets in the original packaging, protect from moisture and heat.

Kaftrio interacts with several medicines; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine): markedly lower Kaftrio exposure. - Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole): substantially raise drug levels. - Simvastatin high doses: increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A inhibitors (e.g., erythromycin, clarithromycin): may elevate exposure modestly. - Oral contraceptives: Kaftrio can reduce hormonal efficacy, consider alternative contraception. - Warfarin: monitor INR as Kaftrio may affect anticoagulant metabolism.